Goldman Sachs
COCH icon

Goldman Sachs’s Envoy Medical COCH Stock Holding History

Goldman Sachs’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,462
Closed -$24.3K – 6623
2026
Q1 		$24.3K Buy
+36,462
New +$24.9K ﹤0.01% 6349
2023
Q1 		– Sell
-200,271
Closed -$2.01M – 5957
2022
Q4 		$2.01M Buy
200,271
+30
+0% +$298 ﹤0.01% 3945
2022
Q3 		$1.97M Sell
200,241
-922,315
-82% -$9.06M ﹤0.01% 3989
2022
Q2 		$11M Hold
1,122,556
– – ﹤0.01% 2427
2022
Q1 		$11M Sell
1,122,556
-155,600
-12% -$1.51M ﹤0.01% 2597
2021
Q4 		$12.4M Hold
1,278,156
– – ﹤0.01% 2556
2021
Q3 		$12.4M Hold
1,278,156
– – ﹤0.01% 2500
2021
Q2 		$12.4M Buy
+1,278,156
New +$12.4M ﹤0.01% 2487

Other funds holding COCH

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCA
DSG Capital Advisors Edina, Minnesota $704M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $242M AUM 20.33% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Goldman Sachs's COCH Position: Q2 2026 in Review

Goldman Sachs sold out of Envoy Medical (COCH) in Q2 2026, closing a stake of 36,462 shares — an estimated $24.3K sold.

Goldman Sachs first reported a position in COCH in Q2 2021 and held it in 8 quarters. The position peaked at $12.4M in Q4 2021. 31 funds tracked by Wall St. Rank hold COCH as of Q2 2026.

  • Goldman Sachs reported no remaining Envoy Medical position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 36,462 Envoy Medical shares in Q2 2026, an estimated $24.3K.
  • Goldman Sachs first reported a position in Envoy Medical in Q2 2021 and held it in 8 quarters.
  • Goldman Sachs's Envoy Medical position peaked at $12.4M in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Envoy Medical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.